FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080551472> ?p ?o ?g. }

• W2080551472 endingPage "3413" @default.
• W2080551472 startingPage "3406" @default.
• W2080551472 abstract "Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-δ, was evaluated in a phase I study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL). Patients had a median (range) age of 64 (32-91) years, 34 (53%) had bulky disease (≥1 lymph nodes ≥5 cm), and 37 (58%) had refractory disease. Patients had received a median (range) of 4 (1-10) prior therapies. Eight dose regimens of idelalisib were evaluated; idelalisib was taken once or twice daily continuously at doses ranging from 50 to 350 mg. After 48 weeks, patients still benefitting (n = 19; 30%) enrolled into an extension study. Adverse events (AEs) occurring in 20% or more patients (total%/grade ≥3%) included diarrhea (36/8), fatigue (36/3), nausea (25/3), rash (25/3), pyrexia (20/3), and chills (20/0). Laboratory abnormalities included neutropenia (44/23), anemia (31/5), thrombocytopenia (25/11), and serum transaminase elevations (48/25). Twelve (19%) patients discontinued therapy due to AEs. Idelalisib induced disease regression in 46/54 (85%) of evaluable patients achieving an overall response rate of 30/64 (47%), with 1 patient having a complete response (1.6%). Median duration of response was 18.4 months, median progression-free survival was 7.6 months. Idelalisib is well tolerated and active in heavily pretreated, relapsed/refractory patients with iNHL. These trials were registered at clinicaltrials.gov as NCT00710528 and NCT01090414." @default.
• W2080551472 created "2016-06-24" @default.
• W2080551472 creator A5000921376 @default.
• W2080551472 creator A5003766253 @default.
• W2080551472 creator A5007034768 @default.
• W2080551472 creator A5007254355 @default.
• W2080551472 creator A5011559739 @default.
• W2080551472 creator A5013974745 @default.
• W2080551472 creator A5015361329 @default.
• W2080551472 creator A5016570475 @default.
• W2080551472 creator A5027453053 @default.
• W2080551472 creator A5029401495 @default.
• W2080551472 creator A5037185685 @default.
• W2080551472 creator A5037882455 @default.
• W2080551472 creator A5048838398 @default.
• W2080551472 creator A5060932518 @default.
• W2080551472 creator A5066010864 @default.
• W2080551472 creator A5069054551 @default.
• W2080551472 creator A5073720570 @default.
• W2080551472 creator A5075675241 @default.
• W2080551472 date "2014-05-29" @default.
• W2080551472 modified "2023-10-12" @default.
• W2080551472 title "Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma" @default.
• W2080551472 cites W1759167934 @default.
• W2080551472 cites W1915689252 @default.
• W2080551472 cites W1976402300 @default.
• W2080551472 cites W1984147944 @default.
• W2080551472 cites W2007667499 @default.
• W2080551472 cites W2027971058 @default.
• W2080551472 cites W2038053631 @default.
• W2080551472 cites W2039175138 @default.
• W2080551472 cites W2054312534 @default.
• W2080551472 cites W2057370954 @default.
• W2080551472 cites W2078948501 @default.
• W2080551472 cites W2082416335 @default.
• W2080551472 cites W2092915615 @default.
• W2080551472 cites W2095447519 @default.
• W2080551472 cites W2102241654 @default.
• W2080551472 cites W2116194748 @default.
• W2080551472 cites W2128936398 @default.
• W2080551472 cites W2133201432 @default.
• W2080551472 cites W2150724746 @default.
• W2080551472 cites W2151963356 @default.
• W2080551472 cites W2152176229 @default.
• W2080551472 cites W2165948908 @default.
• W2080551472 cites W2171771895 @default.
• W2080551472 cites W4248583329 @default.
• W2080551472 cites W68959763 @default.
• W2080551472 doi "https://doi.org/10.1182/blood-2013-11-538546" @default.
• W2080551472 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4260978" @default.
• W2080551472 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24615776" @default.
• W2080551472 hasPublicationYear "2014" @default.
• W2080551472 type Work @default.
• W2080551472 sameAs 2080551472 @default.
• W2080551472 citedByCount "186" @default.
• W2080551472 countsByYear W20805514722014 @default.
• W2080551472 countsByYear W20805514722015 @default.
• W2080551472 countsByYear W20805514722016 @default.
• W2080551472 countsByYear W20805514722017 @default.
• W2080551472 countsByYear W20805514722018 @default.
• W2080551472 countsByYear W20805514722019 @default.
• W2080551472 countsByYear W20805514722020 @default.
• W2080551472 countsByYear W20805514722021 @default.
• W2080551472 countsByYear W20805514722022 @default.
• W2080551472 countsByYear W20805514722023 @default.
• W2080551472 crossrefType "journal-article" @default.
• W2080551472 hasAuthorship W2080551472A5000921376 @default.
• W2080551472 hasAuthorship W2080551472A5003766253 @default.
• W2080551472 hasAuthorship W2080551472A5007034768 @default.
• W2080551472 hasAuthorship W2080551472A5007254355 @default.
• W2080551472 hasAuthorship W2080551472A5011559739 @default.
• W2080551472 hasAuthorship W2080551472A5013974745 @default.
• W2080551472 hasAuthorship W2080551472A5015361329 @default.
• W2080551472 hasAuthorship W2080551472A5016570475 @default.
• W2080551472 hasAuthorship W2080551472A5027453053 @default.
• W2080551472 hasAuthorship W2080551472A5029401495 @default.
• W2080551472 hasAuthorship W2080551472A5037185685 @default.
• W2080551472 hasAuthorship W2080551472A5037882455 @default.
• W2080551472 hasAuthorship W2080551472A5048838398 @default.
• W2080551472 hasAuthorship W2080551472A5060932518 @default.
• W2080551472 hasAuthorship W2080551472A5066010864 @default.
• W2080551472 hasAuthorship W2080551472A5069054551 @default.
• W2080551472 hasAuthorship W2080551472A5073720570 @default.
• W2080551472 hasAuthorship W2080551472A5075675241 @default.
• W2080551472 hasBestOaLocation W20805514721 @default.
• W2080551472 hasConcept C126322002 @default.
• W2080551472 hasConcept C141071460 @default.
• W2080551472 hasConcept C197934379 @default.
• W2080551472 hasConcept C2776694085 @default.
• W2080551472 hasConcept C2777063308 @default.
• W2080551472 hasConcept C2777938653 @default.
• W2080551472 hasConcept C2778461978 @default.
• W2080551472 hasConcept C2778570526 @default.
• W2080551472 hasConcept C2778594517 @default.
• W2080551472 hasConcept C2779260929 @default.
• W2080551472 hasConcept C2779338263 @default.
• W2080551472 hasConcept C2779878957 @default.
• W2080551472 hasConcept C71924100 @default.

• next